New technique shields healthy liver during cancer radiation

NCT ID NCT06229080

Completed Disease control Sponsor: Next Biomedical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a method to protect healthy liver tissue during Yttrium-90 radioembolization, a radiation treatment for liver cancer. Doctors injected short-acting gelatin particles into arteries supplying non-cancerous liver areas to temporarily block blood flow. The goal was to reduce radiation damage to healthy tissue. Twenty adults with primary or metastatic liver cancer participated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gelatin sponge particles (NexGel)
What this could lead to: If successful, this technique could help preserve healthy liver function during radiation treatment for liver cancer, potentially reducing side effects.
What could go wrong: This is a small, early-stage study with only 20 participants and no control group. The approach may not improve outcomes or could cause unexpected complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CANCER (PRIMARY AND METASTATIC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver cancer Liver Neoplasms Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CANCER (PRIMARY AND METASTATIC)

Contacts and locations

Locations

Seoul National University Hospital

Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.